Group 1 - The core point of the article is that Baiotai has signed a licensing and commercialization agreement with Avalon for its BAT3306 (Pabrolizumab) injection, granting Avalon exclusive commercialization rights in Saudi Arabia and the MENA region, with potential total payments up to $7 million [1] - The agreement includes an upfront payment of $2 million, milestone payments not exceeding $5 million, and a percentage of net sales as revenue sharing [1] Group 2 - BAT3306 (Pabrolizumab) is a humanized monoclonal antibody drug developed according to guidelines from NMPA, FDA, and EMA for biosimilars, functioning as an immune checkpoint inhibitor [2] - The drug specifically binds to the PD-1 receptor on lymphocytes, blocking its interaction with PD-L1 and PD-L2, thereby reactivating T cells against tumor cells for cancer treatment [2] - The company is conducting a multicenter, randomized, double-blind, parallel-controlled clinical study to evaluate the pharmacokinetics, immunogenicity, safety, and efficacy of BAT3306 compared to US-Ketruda® in patients with stage IB-IIIA non-small cell lung cancer [2]

Core Viewpoint - The company has signed a licensing, production, supply, and commercialization agreement with Avalon Pharma for the exclusive commercialization rights of BAT3306 (Pablocizumab) injection in Saudi Arabia and the MENA region, which is expected to positively impact future performance and enhance profitability [1] Group 1 - The agreement includes an upfront payment of $2 million [1] - The total milestone payments will not exceed $5 million [1] - The revenue sharing will involve a double-digit percentage of net sales [1] Group 2 - The agreement is effective for fifteen years, with an option to extend for an additional two years [1]